Tikehau Capital: Information Relating to the Total Number of Voting Rights and Shares as of 31 July 2025
Tikehau Capital (Paris:TKO):
Article L. 233-8 II of the French commercial code
Article 223-16 of the General Regulations of the Financial Markets Authority
(1) The notional voting rights correspond to the total number of voting rights which are attached to all the shares, including those with no voting rights (statement in compliance with the article 223-11 of the General Regulations of the Financial Markets Authority).
(2) The exercisable voting rights correspond to the total number of shares exercisable at shareholders meetings. They are calculated on the basis of the total number of voting rights attached to the total number of actions, net of the shares with no voting rights (treasury shares…).
32 rue de Monceau – 75008 Paris
477 599 104 RCS Paris
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
AXA to acquire 51% stake in Italian direct insurer Prima
French insurer AXA has agreed to acquire a 51% share of Prima, a direct insurance provider in Italy, for €500m ($578m), strengthening motor insurance operations in the country. The transaction includes provisions for call/put options pertaining to the remaining 49% of Prima, which will be subject to an exercise price correlated with the company's financial performance. As a managing general agent, Prima operates a proprietary technology platform to distribute its products via various channels including price comparison websites, its own website and a network of more than 1,500 affiliated agents. In fiscal year 2024, Prima reported gross written premiums totalling €1.2bn within Italy. The company operates with a workforce exceeding 1,200 individuals and has established offices in key cities such as Milan, Rome, London and Madrid. Prima CEO George Ottathycal stated: 'We are delighted to become part of the Axa Group. Axa strongly believes in our strategic plan and will provide assets and expertise which will enable Prima to further unlock its potential, leveraging expertise with a leading global insurance Group." AXA's direct distribution segment generated €3.5bn in premiums across multiple geographies in 2024. The move is expected to enhance AXA's direct distribution capabilities in Europe, leveraging Prima's digital infrastructure and expertise. AXA European Markets & Health CEO Patrick Cohen said: 'We are excited to announce the acquisition of Prima, which will not only significantly enhance our position in the Italian P&C [property and casualty] market but also bring capabilities to strengthen our direct business in European markets." The deal is set to conclude by the end of 2025, subject to standard closing conditions and regulatory consents. Upon the deal's completion, existing investors Blackstone, Goldman Sachs and Carlyle will relinquish their investments in Prima, with Neurone continuing to maintain its position as a key shareholder in the company. AXA recently won a London court case against Santander, securing a £680m (€781.53m) ruling for mis-sold payment protection insurance policies. These policies, underwritten by two companies AXA acquired from Genworth in 2015, were originally sold by a company Santander bought in 2009. "AXA to acquire 51% stake in Italian direct insurer Prima " was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
a few seconds ago
- Yahoo
Why TMC The Metals Company Stock Plummeted Last Week
Key Points The Trump administration lifted export restrictions preventing key technologies from being sold to China last week. The export restrictions were suspended in order to help advance trade negotiations between the U.S. and China. Investors are wondering if gaining access to Chinese minerals through a trade deal will mean less need for TMC's seabed mining capabilities. 10 stocks we like better than TMC The Metals Company › TMC The Metals Company (NASDAQ: TMC) stock suffered a big pullback last week in conjunction with geopolitical developments. The seabed-mining specialist's share price fell 24.8% across the stretch. TMC stock got hit with big sell-offs last week in response to news that the U.S. had lifted technology export restrictions preventing high-performance semiconductors and chip manufacturing equipment from being sold to China. While developments that could help facilitate a trade agreement between the U.S. and China have often been bullish catalysts for the broader market, TMC's outlook could actually be better if relations between the two countries remain more adversarial. TMC stock sank on China export news News hit on July 28 that the Trump administration had lifted license requirements that prevented artificial intelligence (AI) processors and semiconductor manufacturing equipment from being sold to China. The move came as part of an effort to advance negotiations for a trade agreement with China. Notably, the U.S. is making continued access to China's rare earth minerals a key pillar of what it's aiming to receive in a trade deal -- and the dynamic has substantial implications for TMC stock. Despite the big pullback, TMC stock is still up 424% across 2025's trading -- and the importance that the Trump administration has placed on improving the United States' mineral sourcing capabilities has been central to the rally. A trade agreement between the U.S. and China has the potential to weaken the company's growth outlook, but there's still a lot of uncertainty as to how things will play out on that front. What's next for TMC? In April, President Donald Trump signed an executive order to accelerate permitting processes needed to advance seabed mining in the U.S., and TMC submitted several permit applications just a few days later. While a trade agreement with China could take some of the urgency out of paving the way for TMC and other players in the seabed mining space to scale their operations, there's a good chance that improving domestic mineral sourcing capabilities will continue to be a national priority. Should you invest $1,000 in TMC The Metals Company right now? Before you buy stock in TMC The Metals Company, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TMC The Metals Company wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why TMC The Metals Company Stock Plummeted Last Week was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
Michael Heinley Joins Sam Brown Healthcare Communications As Managing Director, Client Development and Engagement
-- Heinley to focus on strategic growth, and joins the leadership team of Sam Brown, a Blue Matter Company -- WAYNE, Pa. & NEW YORK, August 04, 2025--(BUSINESS WIRE)--Sam Brown Healthcare Communications, a Blue Matter Company, is proud to announce the appointment of Michael Heinley to the new position of Managing Director, Client Development and Engagement, reporting to Founder and President Laura Liotta. With deep in-house and agency PR experience in the life sciences industry, Heinley is a highly seasoned counselor with a proven record of strategic communications impact across leading global organizations. These include senior leadership roles at Johnson & Johnson, Merck & Co., Inc., and WebMD. Most recently, as Senior Partner in the Finn Partners Global Health Practice, he led client development and engagement for pharmaceutical, biotech, health tech, med tech, health systems, professional societies, and advocacy organizations. "In today's fast-moving and complex healthcare environment, Michael has a distinct perspective leading corporate, scientific, marketing, and brand storytelling campaigns that build trust, strengthen reputation, and deliver meaningful business results," said Laura Liotta, Founder and President of Sam Brown. "In this new role at Sam Brown, Michael will be instrumental in delivering innovative solutions, expanding our services and markets globally, and enabling our integrated teams to help clients adapt and lead in an evolving landscape." Throughout his career, Heinley oversaw multiple global pharmaceutical product launches, R&D communications, employee engagement, financial/IR communications, reputation and issues management, CEO and C-suite counsel, and executive thought leadership. Heinley was named among the industry's most influential leaders and Mentor of the Year by PM360. He currently serves on the Board of Directors for Donate Life New York State, a statewide nonprofit dedicated to increasing organ and tissue donation. "I'm thrilled to join the talented team at Sam Brown to help drive the agency's continued growth and success," said Heinley. "Under Laura's leadership, I've deeply admired the 'Sam Brownie' culture—recognized for building and sustaining enduring client partnerships through strategic expertise, hands-on senior counsel, and integrated creative excellence." About Sam Brown Healthcare Communications For 26 years, Sam Brown has been a leading healthcare-focused corporate, clinical, and commercial communications agency for the life sciences industry. Sam Brown provides broad strategic communications services to a wide range of biotechnology, biopharmaceutical, and venture capital companies whose cutting-edge science and innovation impact human health. For more information, visit About Blue Matter Blue Matter is a strategic consulting firm serving the life sciences industry. From its offices in North America, Europe and Asia, Blue Matter serves pharmaceutical and biotech companies from around the globe. The firm helps clients maximize value at the product, portfolio, and organization levels. It has broad therapeutic expertise with a focus on complex markets such as oncology, CNS, and rare diseases. For more information, visit View source version on Contacts Media Contact: Christy CurranSam Brown Inc.615.414.8668christycurran@ Sign in to access your portfolio
